KPRX.US Kiora Pharmaceuticals Inc

Healthcare Biotechnology USA Stocks
1.23 USD
Close of Nov 15, 2026
1.20 2.91
Market cap
USD 5.44M
P/E
-
P/B
0.32x
ROE
-54.4%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is KPRX.US undervalued?

Graham number

The Graham number of Kiora Pharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Kiora Pharmaceuticals Inc fundamental analysis

No fundamental analysis for Kiora Pharmaceuticals Inc yet.

Kiora Pharmaceuticals Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Kiora Pharmaceuticals Inc

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. The company is also developing KIO-104, a non-steroidal, immuno-modulatory, small-molecule inhibitor of …

Full company profile